28 April 2026
28 April 2026
Ajax’s lead asset is AJ1-11095, a once-daily Type II JAK2 inhibitor taken orally, which is currently in a Phase I trial.
Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines.
The pair will develop drug-digital therapeutic combinations as a singular product, thus sidestepping reimbursement hurdles linked to individually approved digital therapies.
The approval is supported by results from the Phase III TULIP-SC trial.
Recent GlobalData POLI analysis showed a 35% decline in pharmaceutical launches across Europe in the ten months after the introduction of IRP in the US.
Aicuris’s pritelivir is forecast to be a significant advancement for immunocompromised patients with refractory HSV infections.
AI capabilities within pharma are evolving from add-on to an arm of core business demanding overhauled AI governance.
With the introduction of a home testing kit, it is easier for people to get screened for bowel cancer.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
